Patents Assigned to Orexigen Therapeutics, Inc.
-
Publication number: 20110059170Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: ApplicationFiled: July 16, 2010Publication date: March 10, 2011Applicant: OREXIGEN THERAPEUTICS, INC.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20110028505Abstract: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an ?-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: October 12, 2010Publication date: February 3, 2011Applicant: OREXIGEN THERAPEUTICS, INC.Inventors: Anthony A. McKinney, Gary Tollefson, Michael A. Cowley
-
Publication number: 20100190793Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: March 31, 2010Publication date: July 29, 2010Applicant: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20090076108Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: November 5, 2008Publication date: March 19, 2009Applicant: Orexigen Therapeutics, Inc.Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20090018115Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.Type: ApplicationFiled: September 26, 2008Publication date: January 15, 2009Applicant: Orexigen Therapeutics, Inc.Inventors: Kishore M. Gadde, K. Ranga Krishnan
-
Patent number: 7462626Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: February 17, 2006Date of Patent: December 9, 2008Assignee: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 7429580Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.Type: GrantFiled: January 11, 2005Date of Patent: September 30, 2008Assignees: Orexigen Therapeutics, Inc., Duke UniversityInventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Patent number: 7425571Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: GrantFiled: April 23, 2004Date of Patent: September 16, 2008Assignee: Orexigen Therapeutics, Inc.Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20080214592Abstract: Disclosed are methods of treating an anxiety disorder, e.g., obsessive compulsive disorder, in an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to restore normal monoaminergic tone within the synapse.Type: ApplicationFiled: May 2, 2008Publication date: September 4, 2008Applicant: Orexigen Therapeutics, Inc.Inventors: Michael Cowley, Gary Tollefson
-
Patent number: 7375111Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: April 21, 2004Date of Patent: May 20, 2008Assignee: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20080110792Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: ApplicationFiled: November 8, 2007Publication date: May 15, 2008Applicant: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20080113026Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.Type: ApplicationFiled: November 8, 2007Publication date: May 15, 2008Applicant: Orexigen Therapeutics, IncInventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20070281021Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.Type: ApplicationFiled: June 4, 2007Publication date: December 6, 2007Applicant: OREXIGEN THERAPEUTICS, INC.Inventors: Anthony McKinney, Gary Tollefson, Richard Soltero, Thea Dunzo
-
Publication number: 20070275970Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: July 17, 2007Publication date: November 29, 2007Applicant: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Cowley
-
Publication number: 20070270450Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: July 17, 2007Publication date: November 22, 2007Applicant: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Cowley
-
Publication number: 20070185084Abstract: Disclosed are compositions for reversing weight gain comprising a first compound and a second compound, where the first compound is an anticonvulsant and the second compound is a psychotherapeutic agent.Type: ApplicationFiled: January 11, 2007Publication date: August 9, 2007Applicant: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Michael Cowley
-
Publication number: 20070179168Abstract: Disclosed are methods of treating an anxiety disorder, e.g., obsessive compulsive disorder, in an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to restore normal monoaminergic tone within the synapse.Type: ApplicationFiled: November 27, 2006Publication date: August 2, 2007Applicant: Orexigen Therapeutics, Inc.Inventors: Michael Cowley, Gary Tollefson
-
Publication number: 20070148237Abstract: Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.Type: ApplicationFiled: November 27, 2006Publication date: June 28, 2007Applicant: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Simon Yau, Ronald Vladyka, Rick Soltero